Home >> Marketplace Archives >> CMS extends coverage of Oncomine Dx test, 5/18

CMS extends coverage of Oncomine Dx test, 5/18

Print Friendly, PDF & Email

 

May 2018—Thermo Fisher Scientific announced its Oncomine Dx Target Test has been approved for coverage by the Centers for Medicare and Medicaid Services as part of the agency’s national coverage determination for next-generation sequencing in vitro diagnostic tests. Combined with positive reimbursement decisions from commercial health insurers, the test is now available to more than 160 million people in the U.S.

The Oncomine Dx Target Test simultaneously evaluates 23 genes clinically associated with NSCLC.

Thermo Fisher Scientific, 866-356-0354

x

Check Also

Thermo Fisher acquires IntegenX, 5/18

May 2018—Thermo Fisher Scientific has acquired IntegenX, a forensic DNA testing firm. IntegenX products include the RapidHIT platforms, software analysis tools, and related consumables that are compatible with Thermo Fisher’s short tandem repeat chemistries for human identification.

X